Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Estimated results of the logit model. by Yuanquan Lu (17125093)

Subjects:

Estimated annual percentage change in age-standardized prevalence rates of gynecological diseases across 204 countries and territories in 2021. by Xiaofeng He (2618752)

Subjects:

Generalized estimating equation model covariance structure analysis. by Yeo Ju Sohn (18536198)

Land use/ land cover (LULC) change estimates (area and percentage) for Gedaref state for the 1988–1998, 1998–2008, 2008–2018 and 1988–2018. by Maysoon A. A. Osman (16641628)

Subjects:

The PPIC Model, methods and predictions. by Aoife M. Fitzpatrick (13955365)

Subjects:

Modelled monthly changes in colorectal cancer procedure capacity assumed for Canada, based on data from Ontario (treatments and diagnoses) and from OncoSim (diagnoses of screen-det... by Joachim Worthington (8394213)

Subjects:

Comparison of the estimated NPP with measured data. by Qiang Li (8118)

Subjects:

Estimated annual percentage changes in the prevalence rate of specific gynecological diseases from 1990 to 2021, categorized by age group and SDI. by Xiaofeng He (2618752)

Subjects:

Change in influenza vaccination uptake from May 2020 to October 2024 (weighted). by Hannah Melchinger (20234665)

Subjects:

Post-RARP urinary continence recovery stratified by voided volume change. by Yuta Takeshima (818627)

“…<p>Kaplan-Meier curves for post-operative continence recovery to (A) use of 1 pad or less per day, and (B) pad-free status, as stratified by change in voided volume. A statistically significant difference was found for both curves, with a larger decrease in voided volume exhibiting a lower continence rate (log-rank test: P value = 0.011 and 0.008, respectively). …”

CBP per cumulative year for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

Subjects:

S4 Fig - by R. J. S. D. Heine (17889199)

Subjects:

S1 Fig - by R. J. S. D. Heine (17889199)

Subjects:

S5 Fig - by R. J. S. D. Heine (17889199)

Subjects:

Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

Subjects:

S3 Fig - by R. J. S. D. Heine (17889199)

Subjects:

S6 Fig - by R. J. S. D. Heine (17889199)

Subjects:

CBP per cumulative indication for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

Subjects:

Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation. by R. J. S. D. Heine (17889199)

Subjects: